Boston Scientific Reports $5.138 Billion in Third-Quarter Net Sales for 2026 Amid Operational Recovery
Boston Scientific Corporation generated net sales of $5.138 billion during the third quarter of 2026, marking a 1.5 percent increase on a reported, operational, and organic basis compared to the same period in the prior year, the company announced on October 28, 2026. The medical technology manufacturer reported GAAP net income attributable to common stockholders of $582 million, or $0.40 per share, down from $755 million, or $0.51 per share, a year earlier. Adjusted earnings per share reached $0.73 for the period, compared to $0.75 in the third quarter of 2025.
Mike Mahoney, chairman and chief executive officer of Boston Scientific, pointed to a difficult operational backdrop while addressing the results. “This has been a challenging year for Boston Scientific and I’m proud of how our global teams have responded, particularly to the cybersecurity incident, working with urgency and resilience to restore operations and continue supporting customers and patients,” Mahoney said.
The Marlborough, Massachusetts-based device maker experienced varied performance across its reportable business segments. The Cardiovascular division recorded net sales of $3,406 million, up 1.9 percent on reported, operational, and organic bases. Meanwhile, the MedSurg segment generated $1.722 billion, representing growth of 0.6 percent on a reported basis and 0.7 percent on both operational and organic bases. Within MedSurg, Endoscopy sales dipped 0.6 percent organically to $747 million, Urology sales declined 3.1 percent organically to $682 million, and Neuromodulation grew 13.0 percent organically to reach $293 million.
Boston Scientific Reports US Sales Growth and Updates 2026 Outlook
Geographic performance diverged significantly across international markets during the quarter. The United States market delivered $3.294 billion in net sales, marking a 0.5 percent increase on reported and operational bases.
Eastern Time. Alongside the quarterly figures, Boston Scientific updated its financial outlook for the remainder of the year. The company estimates full-year 2026 net sales growth of approximately 4.25 percent on a reported basis and approximately 3.75 percent on an organic basis, with adjusted earnings per share projected between $3.16 and $3.18. For the fourth quarter of 2026, the company projects net sales to decline by approximately 3.0 to 1.0 percent on reported and organic bases, with adjusted earnings per share estimated between $0.77 and $0.79.
